Valmedika - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 62,025 | 64,185 | 1,671 | 2,858 | 1,412 | 18,824 | 30,000 | 10,000 |
| Profit before tax | 25,737 | - | - | - | - | 8,582 | 11,744 | -18,831 |
| Net profit | 24,430 | 4,682 | -6,183 | -4,367 | -11,906 | 8,115 | 11,212 | -18,831 |
| Equity | 34,380 | 39,061 | 32,879 | 28,513 | 16,607 | 24,722 | 35,934 | 17,103 |
| Liabilities | 15,685 | 14,722 | 14,579 | 14,948 | 16,275 | 758,636 | 157,023 | 157,166 |
| Non-current assets | 6,509 | 7,919 | 5,760 | 4,821 | 17,148 | 779,612 | 155,376 | 131,618 |
| Current assets | 43,556 | 45,864 | 41,698 | 38,640 | 15,734 | 2,918 | 35,223 | 40,848 |
| Total assets | 50,065 | 53,783 | 47,458 | 43,461 | 32,882 | 782,530 | 190,599 | 172,466 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 50 | - | 664 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +24.4% | +3.5% | -97.4% | +71.0% | -50.6% | +1233.1% | +59.4% | -66.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 48.8% | 8.7% | -13.0% | -10.0% | -36.2% | 1.0% | 5.9% | -10.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 71.1% | 12.0% | -18.8% | -15.3% | -71.7% | 32.8% | 31.2% | -110.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 39.4% | 7.3% | -370.0% | -152.8% | -843.2% | 43.1% | 37.4% | -188.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 41.5% | - | - | - | - | 45.6% | 39.1% | -188.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.5 | 0.4 | 0.4 | 0.5 | 1.0 | 30.7 | 4.4 | 9.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 31,013 | 32,093 | 836 | 1,429 | 706 | 9,412 | 15,000 | 5,000 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Valmedika - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-03-03 | 2025-03-03 | 0.02 |
| 2025-02-18 | 2025-02-27 | 0.02 |
| 2025-02-10 | 2025-02-10 | 0.02 |
| 2025-01-22 | 2025-02-02 | 0.02 |
| 2024-10-16 | 2024-10-20 | 12.12 |
| 2024-04-23 | 2024-05-15 | 0.02 |
| 2024-02-19 | 2024-02-20 | 12.12 |
Valmedika - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Valmedika, UAB (code 304168023) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated €10.0K in revenue and reported a net loss of €18.8K, after posting net profit of €11.2K in 2024 and €8.1K in 2023. Revenue increased from €18.8K in 2023 to €30.0K in 2024, but then fell sharply in 2025, with the business moving back into loss. The latest loss was large relative to turnover, so profitability weakened materially. Balance sheet indicators also remained modest: total assets stood at €172.5K in 2025, compared with €190.6K in 2024 and €782.5K in 2023, while equity declined to €17.1K from €35.9K and liabilities were €157.2K. The equity ratio was 9.9% and debt to equity was 9.19, indicating limited capitalization. Asset turnover was 0.06x. Revenue per employee was €5.0K, and profit per employee was -€9.4K, reflecting weak operating productivity in 2025.